A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Exclusion Criteria

• •Patients who meet any of the following criteria will be excluded from study entry:
• •1. Treatment with any of the following:
• •* Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days).
• •* Systemic chemotherapy within 14 days.
• •* Radiation therapy within 14 days
• •* Biologics (Antibodies) treatment within 28 days,
• •* Radioimmunoconjugates or toxin conjugates within 12 weeks.
• •* Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
• •* Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD.
• •2. History of central nervous system lymphoma/leukemia in remission for less than 2 years.
• •3. Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.